Savi A, Gerundini P, Zoli P, Maffioli L, Compierchio A, Colombo F, Matarrese M, Deutsch E
Department of Nuclear Medicine, Istituto San Raffaele, Milano.
Eur J Nucl Med. 1989;15(9):597-600. doi: 10.1007/BF00256936.
Hexakis (methoxyisobutilisonitrile) technetium(I), 99mTc-MIBI, has been proposed for myocardial perfusion studies. We have evaluated the biodistribution of this new agent in normal volunteers at rest and after stress. The biodistribution of 99mTc-MIBI is characterized by rapid blood clearance and a consequently early myocardial uptake. The initial intense hepatic activity is cleared into the gallbladder at 1 h after injection, and the best target to non target ratio is observed at 60-90 min after injection. Absorbed radiation dose calculations show that the thyroid is the critical target organ (230 mRad/mCi at rest), presumably because of 99mTc-pertechnetate generated in vivo. Our results indicate that 99mTc-MIBI is a promising tracer for myocardial perfusion imaging.
六甲基异丁基异腈锝（I），即99mTc-MIBI，已被推荐用于心肌灌注研究。我们评估了这种新型药物在静息和应激状态下正常志愿者体内的生物分布。99mTc-MIBI的生物分布特点是血液清除迅速，因而心肌摄取较早。注射后1小时，最初强烈的肝脏活性会排入胆囊，在注射后60 - 90分钟观察到最佳的靶与非靶比值。吸收辐射剂量计算表明，甲状腺是关键靶器官（静息时为230毫拉德/毫居里），这可能是由于体内生成了高锝酸盐99mTc。我们的结果表明，99mTc-MIBI是一种有前景的心肌灌注显像剂。
